The NCI wants to encourage clinical trial investigators to review data from their completed clinical trials and treating oncologists to look back in their patient records to identify potential cases of exceptional responses and submit them for consideration in the initiative.
As part of its Exceptional Responders Initiative, the National Cancer Institute (NCI) continues to reach out to the oncology community.
The initiative is collecting cases in which patients with any cancer had dramatic and long-lasting responses to standard and experimental treatments that were not seen in similar patients who received the same treatment.
By studying tissue, clinical, and genomic data from these patients, NCI scientists hope to learn whether such exceptional responses can provide broader insights into the genetic mechanisms that underlie such responses and suggest therapeutic options that weren’t previously apparent, explained Barbara Conley, MD, of NCI’s Division of Cancer Treatment and Diagnosis.
Link to the complete article on NCI's website:
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
NCCN Data Find Racial, Socioeconomic Disparities in Quality of Care for Metastatic Pancreatic Cancer
April 9th 2025New data from the National Comprehensive Cancer Network (NCCN) reveal that socially vulnerable and minority patients with metastatic pancreatic cancer are less likely to receive recommended treatments and achieve longer survival.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen